Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07137338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Jun 2026 to Apr 17, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 6 entries
  2. Site contacts updated at 1 of 3 sitesv5
  3. Site details revised at 2 of 3 sitesv4
  4. Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    v3
  5. Eligibility criteria expanded, about 1 wordv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Trial Details
NCT Number NCT07137338
Lead Sponsor Rocket Pharmaceuticals Inc.
Conditions
(from sponsor)		 Dilated Cardiomyopathy (DCM)
Related terms Cardiomyopathies, Cardiomyopathy, Dilated, Cardiovascular Diseases, Dilatation, Pathologic, Heart Diseases, Heart Failure
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov